Rifaximin (Xifaxanta®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000538
English
Authors' recommendations:
Rifaximin (Xifaxanta®) is recommended as an option for use within NHS Wales for the treatment of travellers' diarrhoea that is not associated with any of: fever, bloody diarrhoea, eight or more unformed stools in the previous 24 hours, occult blood or leucocytes in the stool or to shorten the duration of diarrhoea when this is associated with non-invasive strains of E.coli.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=194847&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Anti-Bacterial Agents
- Travel
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.